Tusneem Elhassan
Overview
Explore the profile of Tusneem Elhassan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gaafar A, Hamza F, Yousif R, Shinwari Z, Alotaibi A, Iqniebi A, et al.
Diagnostics (Basel)
. 2025 Feb;
15(4).
PMID: 40002599
We aimed to identify the molecular signatures of primitive CD34 and CD34 hematopoietic stem/progenitor cell (HSC/HPC) subsets in cord blood and bone marrow samples. CD34 and CD34 HSC/HPC subsets from...
2.
Mobeireek A, Weheba I, Ezzat L, Hajji M, Rasheed W, Elhassan T, et al.
Transpl Infect Dis
. 2025 Jan;
e14441.
PMID: 39826141
Background: The role of fiberoptic bronchoscopy (FOB) in the management of patients presenting with pulmonary infiltrates after hematopoietic stem cell transplant (HSCT) remains unclear. We aimed to evaluate the diagnostic...
3.
Aseafan M, Alfakeeh A, Tashkandi E, Mahrous M, Alghamdi M, Alshamsan B, et al.
BMC Cancer
. 2025 Jan;
25(1):7.
PMID: 39754118
Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited treatment options yielding poor outcomes. This study aimed to evaluate the real-world clinical characteristics, treatment patterns,...
4.
Elhassan T, Osman A, Mohd Rahim M, Mohd Hashim S, Ali A, Elhassan E, et al.
Heliyon
. 2024 Oct;
10(19):e37745.
PMID: 39386823
Acute myeloid leukemia (AML) is a highly aggressive cancer form that affects myeloid cells, leading to the excessive growth of immature white blood cells (WBCs) in both bone marrow and...
5.
Bekadja M, Niederwiser D, Kharfan-Dabaja M, El Fakih R, Garderet L, Yakoub-Agha I, et al.
Bone Marrow Transplant
. 2024 Oct;
60(1):19-27.
PMID: 39375527
Autologous peripheral blood stem cell (PBSC) transplantation is a standard treatment of multiple myeloma (MM), Hodgkin lymphoma and various subtypes of non-Hodgkin lymphoma. Cryopreservation of hematopoietic stem cells is standard...
6.
Alshamsan B, Elshenawy M, Aseafan M, Fahmy N, Badran A, Elhassan T, et al.
Oncol Lett
. 2024 Jul;
28(3):429.
PMID: 39049989
The present study aimed to clarify the prognostic role of the pre-treatment neutrophil-to-lymphocyte ratio (NLR) for the response to neoadjuvant chemotherapy (NAC) in locally advanced breast cancer (LABC). Due to...
7.
Alhusaini H, Badran A, Al Juhani A, Alshamsan B, Alsagaih Y, Alqayidi A, et al.
Mol Clin Oncol
. 2024 Jun;
21(1):47.
PMID: 38872951
Low-grade serous ovarian cancer (LGSOC) is a very rare histological subtype of serous ovarian cancer, representing ~2% of all epithelial ovarian cancer cases. LGSOC has a better prognosis but a...
8.
Elshenawy M, Arabi T, Ateya H, Elhassan T, Ali S, Othman R, et al.
Cureus
. 2024 May;
16(4):e58292.
PMID: 38752067
Background: Giant cell tumor of the bone (GCTB) is an aggressive benign tumor, which constitutes 5% of all primary bone tumors. Denosumab, a receptor activator of nuclear factor κB ligand...
9.
Solaiman O, Elhassan T, Fakih R, Mannan A, Alduhailib Z, Mahdali A, et al.
Hematol Oncol Stem Cell Ther
. 2024 Apr;
17(2):110-119.
PMID: 38560973
Background And Objectives: Prognostic factors reliably predicting outcomes for critically ill adolescent and young adult (AYA) patients undergoing allogeneic hematopoietic cell transplantation (allo-HSCT) are lacking. We assessed transplant and intensive...
10.
Bazarbashi S, Alkhatib R, Aseafan M, Tuleimat Y, Abdel-Aziz N, Mahrous M, et al.
JCO Glob Oncol
. 2024 Mar;
10:e2300461.
PMID: 38484194
Purpose: Metastatic colorectal cancer (mCRC) is a significant global health burden. This retrospective study compared the effectiveness of trifluridine/tipiracil (FTD/TPI), regorafenib, and chemotherapy rechallenge for third-line mCRC treatment. Materials And...